Chinese biopharmaceutical company Mabwell (SH:688062) announced on Friday that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance from China's National Medical Products Administration (NMPA) and an IND Acknowledgement Letter from the US Food and Drug Administration (FDA).

7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's proprietary IDDC platform. The company says that its highly optimised structure integrates three key elements: Mab0727, a highly specific CDH17 monoclonal antibody with rapid internalisation properties, cross-species (human/monkey) moderate affinity, and minimal off-target binding; novel cleavable linker, ensuring precise payload release in tumour tissues; and MF-6 payload, a proprietary DNA topoisomerase I inhibitor designed to overcome multidrug resistance (MDR), exhibiting superior plasma stability, controlled drug release, and potent bystander effects.

Mabwell claims that with this profile, 7MW4911 is a promising therapeutic candidate for advanced gastrointestinal cancers.